about
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesChallenges of recurrent hepatitis C in the liver transplant patientPrognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantationActivation of the transforming growth factor-β/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma.Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation.Clinical implications of basic research in hepatocellular carcinoma.Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma.Management of Immunosuppression in Liver Transplantation.Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.Transcriptional Induction of Periostin by a Sulfatase 2-TGFβ1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma.Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptorsRare case of adult undifferentiated (embryonal) sarcoma of the liver treated with liver transplantation: excellent long-term survival.Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/β-catenin-induced FGF18 expression in hepatocellular carcinoma.YAP-associated chromosomal instability and cholangiocarcinoma in mice.Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.Response to Fibrosis progression in patients treated for hepatitis C recurrence.Response to Houlihan et al.Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsGenomic Medicine and Implications for Hepatocellular Carcinoma Prevention and TherapyErratum to “Clinical implications of basic research in hepatocellular carcinoma” [J Hepatol 2016;64:736–745]Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinomaTumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapyComparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)and cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunityThe effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinomaDirect-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort StudyDirect-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular CarcinomaA Tale of Two Complications of Obesity: NASH and Hepatocellular CarcinomaOne world, one pandemic, many guidelines: management of liver diseases during COVID-19
P50
Q26745338-C156532D-2E02-4768-BAF7-783744CA36DAQ27011871-BB2ACE32-C898-4CB7-8E0F-AAFE78CC35D3Q33928147-CE5AF1A9-582A-46F4-95F7-886A7A02CFD5Q35162986-0A725017-782A-40D7-AE8E-F0CBAB1C1A2DQ35224629-BE1B703E-C67A-4B5E-BEAA-F8A41D2017FDQ36880485-2F40CEA8-F011-4FF9-98C3-FBF9B3A6FC67Q37289933-48E61BDA-A30C-4B84-9258-067837A6C8FBQ38236632-6482334C-95D3-49C0-BBFE-2F77907F5D49Q38560093-8932E4A1-8435-4562-80DA-C7574BB32625Q39212641-509B003C-8E73-45A3-8D90-EE1BD0E30C24Q40450035-6AE954FE-893A-48A3-8CC8-D23571AD23F9Q40463354-59712D45-5B89-4E0F-9F8A-A1151A494FEBQ41172899-AA54CEF2-2CDE-4ABC-B13C-24E07A5CEB4AQ42011268-06299039-ED22-4BC6-B1DE-911DB200FD7FQ42959757-C7FFC01F-225A-4238-A2B8-52B954435FFAQ47291861-B0DB53FF-824C-435D-8AB7-C0FC0A1BBD00Q49787756-5AC3CA3D-F746-4109-8464-191C58DF7DA3Q49787968-FD1CD8C5-2C20-4111-84F4-B74F0AB7CEEDQ50874882-35F73C8A-9CCF-4448-9F52-7ECBB42094DBQ50961212-F4C8B534-7675-4A18-9B49-749B8D53EB2BQ54658133-F5F17B69-7A1B-4DC6-ADD1-13B890B3F736Q57261157-C1980C23-18EB-4D76-87A2-F60A32421F2FQ58612842-E9541B63-2F51-4CF1-B747-BBAD13F68A84Q59150525-F86A3BE1-1882-40F5-B57B-3BF6C989ED6CQ59329905-1F07CD6D-C6D3-48F0-BE20-6E1DED4E5B38Q82528450-9DD84642-61F2-4479-8643-CB5332E39C29Q83157920-21452EB1-C50A-4DA4-ABE6-EAAD4F62A606Q83224538-D59C0D42-DB9B-4B2E-9867-BABB918C573AQ84591421-9B882116-7BA3-46C8-890D-B77750B594E3Q91124506-156B5A7E-A34F-4C1A-89CF-427DB0E3F843Q92368938-04277AF5-6FE3-439E-BA79-C8735E941C54Q92926773-0FC16B71-69C6-4821-B0C4-2A96CA500274Q96134319-3DE8A591-2A45-460E-B541-8D22F83E0EFC
P50
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Renumathy Dhanasekaran
@ast
Renumathy Dhanasekaran
@en
Renumathy Dhanasekaran
@es
Renumathy Dhanasekaran
@nl
type
label
Renumathy Dhanasekaran
@ast
Renumathy Dhanasekaran
@en
Renumathy Dhanasekaran
@es
Renumathy Dhanasekaran
@nl
prefLabel
Renumathy Dhanasekaran
@ast
Renumathy Dhanasekaran
@en
Renumathy Dhanasekaran
@es
Renumathy Dhanasekaran
@nl
P106
P1153
35782908700
P31
P496
0000-0001-8819-7511